Amneal Pharmaceuticals (AMRX) Gross Profit (2017 - 2026)

Amneal Pharmaceuticals' Gross Profit history runs 10 years deep, the most recent figure standing at $320.1 million for Q1 2026.

• In Q1 2026, Gross Profit rose 25.1% year-over-year to $320.1 million; the TTM figure through Mar 2026 stood at $1.2 billion (up 13.41% YoY), while the FY2025 annual figure was $1.1 billion, up 9.1% from the prior year.
• Gross Profit was $320.1 million for Q1 2026 at Amneal Pharmaceuticals, up from $297.2 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $320.1 million in Q1 2026 to a low of $174.6 million in Q1 2022.
• Historically, Gross Profit has averaged $238.8 million across 5 years, with a median of $238.1 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Gross Profit declined 11.87% in 2023, then soared 38.48% in 2024.
• A 5-year view of Gross Profit shows it stood at $215.4 million in 2022, then retreated by 11.87% to $189.8 million in 2023, then soared by 38.48% to $262.9 million in 2024, then increased by 13.05% to $297.2 million in 2025, then grew by 7.71% to $320.1 million in 2026.
• The last three Gross Profit figures came in at $320.1 million (Q1 2026), $297.2 million (Q4 2025), and $274.0 million (Q3 2025), per Business Quant data.